Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | TYMS | P04818 | 4/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6508609 | 0.91 | CA2 (0.47) | KDM4EHPGDCA2CA1CA12 | |
| SCHEMBL4397295 | 0.88 | KDM4E (0.47) | KDM4EHPGDCA2CA1CA12 | |
| SCHEMBL6510663 | 0.88 | KDM4E (0.47) | KDM4EHPGDCA2CA1CA12 | |
| SCHEMBL6509910 | 0.85 | KDM4E (0.40) | KDM4EHPGDCA2CA1CA12 | |
| SCHEMBL6509677 | 0.84 | KDM4E (0.46) | KDM4EHPGDCA2CA1CA12 | |
| SCHEMBL6512041 | 0.79 | CA2 (0.47) | KDM4EHPGDCA2CA1CA12 | |
| SCHEMBL21586412 | 0.76 | KDM4E (0.58) | KDM4EHPGDCA2CA1CA12 | |
| SCHEMBL18263949 | 0.76 | KDM4E (0.58) | KDM4EHPGDCA2CA1CA12 | |
| SCHEMBL6511464 | 0.76 | CA2 (0.49) | KDM4EHPGDCA2CA1FOLH1 | |
| SCHEMBL6509854 | 0.76 | CA2 (0.45) | KDM4EHPGDCA2CA1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852755-B1 | Nitrogen mustard compounds and prodrugs therefor | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2005-02-08 | — | — | US | claimed |
| EP-1165493-B1 | NITROGEN MUSTARD COMPOUNDS AND PRODRUGS THEREFOR | CANCER REC TECH LTD (GB) | 2005-01-19 | — | — | EP | claimed |
| EP-1165493-A1 | NITROGEN MUSTARD COMPOUNDS AND PRODRUGS THEREFOR | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2002-01-02 | — | — | EP | claimed |
| WO-2000058271-A1 | NITROGEN MUSTARD COMPOUNDS AND PRODRUGS THEREFOR | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-10-05 | — | — | WO | claimed |
| US-6858584-B2 | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin | THERAVANCE, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-6852755-B1 | Nitrogen mustard compounds and prodrugs therefor | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2005-02-08 | — | — | US | disclosed |
| EP-1165493-B1 | NITROGEN MUSTARD COMPOUNDS AND PRODRUGS THEREFOR | CANCER REC TECH LTD (GB) | 2005-01-19 | — | — | EP | disclosed |
| US-20040014187-A1 | Bacterial carboxypeptidase cpg2 variants and their use in gene directed enzyme prodrug therapy | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2004-01-22 | — | — | US | disclosed |
| EP-1280921-A1 | BACTERIAL CARBOXYPEPTIDASE CPG2 VARIANTS AND THEIR USE IN GENE DIRECTED ENZYME PRODRUG THERAPY | Cancer Research Ventures Limited (GB) | 2003-02-05 | — | — | EP | disclosed |
| EP-1165493-A1 | NITROGEN MUSTARD COMPOUNDS AND PRODRUGS THEREFOR | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001085960-A1 | BACTERIAL CARBOXYPEPTIDASE CPG2 VARIANTS AND THEIR USE IN GENE DIRECTED ENZYME PRODRUG THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| WO-2000058271-A1 | NITROGEN MUSTARD COMPOUNDS AND PRODRUGS THEREFOR | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-10-05 | — | — | WO | disclosed |